Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Edema|Erythema|Estrogen Receptor Negative|HER2/Neu Negative|Peau d'Orange|Progesterone Receptor Negative|Recurrent Inflammatory Breast Carcinoma|Stage IV Inflammatory Breast Carcinoma|Triple-Negative Breast Carcinoma
Interventions: OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Pembrolizumab
Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)